China has approved a weight-loss pill developed by a US pharmaceutical company, opening the door to increased competition in the country’s rapidly growing obesity treatment market.
According to a report by The News International, the approval was granted on November 12, 2026, potentially giving the US company an advantage over a Danish pharmaceutical competitor in China’s major medicines market.
The newly approved drug belongs to a class of medicines that helps reduce appetite and regulate blood sugar levels.
Unlike injectable weight-loss treatments, the medication is designed to be taken as a daily pill. Its use does not require any specific restrictions on eating or drinking, according to the report.
China’s National Health Commission has projected that the proportion of people who are overweight or obese in the country could exceed 65 per cent by 2030.
The growing prevalence of obesity is expected to increase demand for weight-management medicines in the country.

